ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Blood Test Discussion
high hematocrit/hemoglobin - what to do
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Vince" data-source="post: 216190" data-attributes="member: 843"><p>Two large pharmacoepidemiological studies have compared the rate of venous thromboembolism in men receiving testosterone treatment versus a control group (men not receiving testosterone treatment).<a href="https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref39" target="_blank">39,</a><a href="https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref40" target="_blank">40</a> The first study – which we have presented previously “<a href="https://www.nebido.com/hcp/testosterone-news-resources/research-news/risk-of-venous-thromboembolism-in-men-receiving-testosterone-therapy" target="_blank"><strong>Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy</strong></a>” - showed that testosterone treatment is not associated with an increased risk of venous thromboembolism.<a href="https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref39" target="_blank">39</a> The second study concluded that starting testosterone treatment is associated with an increased risk of venous thromboembolism during the first 6 months of testosterone treatment, and declines thereafter.<a href="https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref40" target="_blank">40</a> A meta-analysis was recently conducted on these two studies.<a href="https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref33" target="_blank">33</a> A meta-analysis is a statistical approach to combine the results from multiple studies in an effort to increase statistical power (over individual studies), improve estimates of the effect size and/or to resolve uncertainty when studies disagree.<a href="https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref41" target="_blank">41,</a><a href="https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref42" target="_blank">42</a> This meta-analysis showed that testosterone treatment is not associated with an increased risk of venous thromboembolism, even when the analysis was confined to the first 6 months of testosterone therapy. Risk of blood clots seems to be more strongly associated with estrogen and estrogen treatment. The contribution of estrogen as a causal factor in venous thromboembolism is supported by the World Professional Association for Transgender Health (WPATH), which report that the greatest risk factor of male-to-female estrogen hormone treatment is venous thromboembolism. This is not the case in female-to-male transsexuals, who are treated with testosterone.</p><p></p><p>[URL unfurl="true"]https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots[/URL]</p></blockquote><p></p>
[QUOTE="Vince, post: 216190, member: 843"] Two large pharmacoepidemiological studies have compared the rate of venous thromboembolism in men receiving testosterone treatment versus a control group (men not receiving testosterone treatment).[URL='https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref39']39,[/URL][URL='https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref40']40[/URL] The first study – which we have presented previously “[URL='https://www.nebido.com/hcp/testosterone-news-resources/research-news/risk-of-venous-thromboembolism-in-men-receiving-testosterone-therapy'][B]Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy[/B][/URL]” - showed that testosterone treatment is not associated with an increased risk of venous thromboembolism.[URL='https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref39']39[/URL] The second study concluded that starting testosterone treatment is associated with an increased risk of venous thromboembolism during the first 6 months of testosterone treatment, and declines thereafter.[URL='https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref40']40[/URL] A meta-analysis was recently conducted on these two studies.[URL='https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref33']33[/URL] A meta-analysis is a statistical approach to combine the results from multiple studies in an effort to increase statistical power (over individual studies), improve estimates of the effect size and/or to resolve uncertainty when studies disagree.[URL='https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref41']41,[/URL][URL='https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots#fn:ref42']42[/URL] This meta-analysis showed that testosterone treatment is not associated with an increased risk of venous thromboembolism, even when the analysis was confined to the first 6 months of testosterone therapy. Risk of blood clots seems to be more strongly associated with estrogen and estrogen treatment. The contribution of estrogen as a causal factor in venous thromboembolism is supported by the World Professional Association for Transgender Health (WPATH), which report that the greatest risk factor of male-to-female estrogen hormone treatment is venous thromboembolism. This is not the case in female-to-male transsexuals, who are treated with testosterone. [URL unfurl="true"]https://www.nebido.com/hcp/research-news/hematocrit-elevation-following-testosterone-therapy-and-risk-of-blood-clots[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Blood Test Discussion
high hematocrit/hemoglobin - what to do
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top